



available at [www.sciencedirect.com](http://www.sciencedirect.com)



journal homepage: [www.ejconline.com](http://www.ejconline.com)



## Corrigendum

# Corrigendum to “Promises borne out in clinical studies” [EJC Supplements 6 (5) (2008) 15–24]

**David Cameron\***

National Cancer Research Network, Coordinating Centre, 24 Hyde Terrace, Leeds LS2 9LN, United Kingdom

The author wishes to correct the 3rd sentence of the Conclusions on page 22 as follows:

Importantly, lapatinib is the only agent in development that has Level 1 evidence of clinical efficacy in patients with HER2-positive advanced or metastatic breast cancer following at least one line of trastuzumab containing regimen in the metastatic setting.

DOI of original article: [10.1016/S1359-6349\(08\)70276-3](https://doi.org/10.1016/S1359-6349(08)70276-3)

\* Tel.: +44 113 343 8033; fax: +44 113 343 2242.

E-mail address: [d.cameron@ncrn.org](mailto:d.cameron@ncrn.org).

0959-8049/\$ - see front matter © 2008 Elsevier Ltd. All rights reserved.

doi:10.1016/j.ejca.2008.06.039